Durham Nephrology Associates was selected to be part of the high performing investigative sites comprising F1RST Up–a program to accelerate study startup for renal research. We were selected as a research site because of our expertise in renal research and track record of timely and quality patient care.
Under the direction of Dr. Amarnath Kathresal, we have partnered with Frenoval Renal Research to conduct clinical trials. Frenova Renal Research, a Fresenius Medical Care North America company, is the only Phase I-IV drug and device clinical development services provider dedicated exclusively to renal research. Frenova provides access to the largest renal research site network in the world.
Through F1RST Up, physicians and medical researchers are able to get their renal studies online faster than ever before.
With access to nearly 180,000 chronic kidney disease patients and 16,500 end-stage renal disease patients, historical data on hundreds of thousands of patients with kidney disease, and one of the nation’s largest renal biometric databases, no other clinical development services provider has a more intimate understanding of patients affected by kidney disease and its associated conditions.
Being a member of this exclusive alliance of world-class renal research sites is just one example of how Durham Nephrology works continuously to better understand the complexities of kidney disease. The valuable research collected through this program will drive the innovation of new treatment methods and allow us to continue delivering the highest quality patient care possible.
To learn more about this program or to schedule an appointment with Durham Nephrology Associates, call (919) 477-3005.
